Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces that it has won the \u201cBest ADC Platform Technology\u201d category at the 2020 World ADC Awards ceremony. Synaffix\u2019 ADC platform consists of GlycoConnect\u2122, HydraSpace\u2122 and toxSYN\u2122 which comprise site-specific technology and payloads to enable best-in-class ADCs.<\/p>\n\n\n\n
Synaffix was presented the award during the 2020 World ADC Digital event. The finalists were shortlisted through a voting pool of over 1,000 individuals, with a panel of distinguished,independent industry experts from across the ADC field, assessing each finalist to decide the winners.<\/p>\n\n\n\n
The judging panel highlighted the following three cornerstone features of the Synaffix ADC platform:
\u2022 Consistent delivery of highly competitive ADC product candidates
\u2022 Strong commercial and scientific validation (over $420m in out-licensing deals, at least six ADCs in development with two in clinical trials)
\u2022 Compatible and easy to use with any antibody<\/p>\n\n\n\n
Peter van de Sande, CEO of Synaffix, said: \u201cWe are greatly honored to be recognized with the award for Best ADC Platform Technology as voted by our industry peers. Our team has worked passionately to provide cutting-edge ADC-enabling technologies, and we have now built what we believe to be an industry-leading platform to enable best-in-class ADC product candidates. Being recognized with this award serves to validate the significant efforts we have already made towards becoming the most prevalent technology across new clinical-stage ADCs.\u201d<\/p>\n\n\n\n